Amundi Acquires 13,041 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Amundi grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 243.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,402 shares of the company's stock after purchasing an additional 13,041 shares during the period. Amundi's holdings in Harmony Biosciences were worth $635,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HRMY. Pacer Advisors Inc. grew its stake in shares of Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after buying an additional 351,582 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company's stock worth $26,416,000 after acquiring an additional 140,690 shares in the last quarter. HealthInvest Partners AB increased its stake in shares of Harmony Biosciences by 335.2% during the 3rd quarter. HealthInvest Partners AB now owns 151,875 shares of the company's stock worth $6,075,000 after purchasing an additional 116,975 shares during the last quarter. Capital Management Corp VA raised its holdings in shares of Harmony Biosciences by 43.5% during the 4th quarter. Capital Management Corp VA now owns 340,960 shares of the company's stock valued at $11,732,000 after purchasing an additional 103,308 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Harmony Biosciences by 27.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 472,028 shares of the company's stock valued at $16,242,000 after purchasing an additional 100,586 shares during the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

HRMY has been the topic of several analyst reports. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective on the stock. HC Wainwright cut their price objective on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, February 25th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $53.33.

Harmony Biosciences Stock Performance

HRMY traded down $1.04 during midday trading on Monday, reaching $34.24. The company's stock had a trading volume of 593,085 shares, compared to its average volume of 527,250. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $36.42 and a 200 day simple moving average of $35.58. The stock has a market cap of $1.96 billion, a P/E ratio of 16.23, a PEG ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.11. The business had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter last year, the company posted $0.45 earnings per share. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Transactions at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jeffrey Dierks sold 1,123 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by company insiders.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.